Sign up to save your podcasts
Or
Share Part 2 - Myeloma: The New Playbook
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Part 2 - Myeloma: The New Playbook
Highlights include:
• Early detection and the potential of screening studies like PROMISE and iStopMM
• Modifiable risk factors—how diet, exercise, and inflammation shape disease and outcomes
• Emerging therapies on the horizon
• Why “down with dex” and other old beliefs deserve retirement
• The personal “why” behind every advance in myeloma care
About the Experts
Dr. Paul Richardson
Dr. Paul Richardson is an internationally recognized visionary in hematology and oncology whose trailblazing research at Dana-Farber Cancer Institute and Harvard Medical School has driven therapeutic revolutions in multiple myeloma, transforming patient outcomes and defining today’s standards of care. In addition to his involvement in the approval of nearly every major therapy for the disease over the past two decades, he is also one of the most prolific and cited experts in the field, with nearly 500 original articles and 400 reviews.
Dr. Richardson is a paid consultant for BMS.
Dr. Joseph Mikhael
Dr. Joseph Mikhael has revolutionized and broadened access to world-class myeloma care globally through his pioneering leadership at TGen and the International Myeloma Foundation and as principal investigator of numerous groundbreaking clinical trials, setting new benchmarks in innovation, impact, and equity. Celebrated as a dynamic champion for underserved communities, an award-winning educator, and a masterful communicator, Dr. Mikhael has authored over 150 influential scientific articles and was recently recognized among America’s Top 100 Doctors for his transformational contributions to the field.
Dr. Mikhael was not compensated for his participation.
Dr. Mecide Gharibo
Dr. Mecide Gharibo is an innovative hematology leader whose passion for transforming patient care extends from academic clinical expertise at Rutgers Cancer Institute to launching breakthrough therapies as Global Head of Hematology at Bristol Myers Squibb. Renowned for advancing life-saving treatments and optimizing patient access, Dr. Gharibo’s clinical excellence and senior pharmaceutical leadership have fueled medical innovation and set new standards for care through a proven record of successful therapy approvals.
Dr. Gharibo is an employee of BMS.
View all episodes
By Bristol Myers SquibbHighlights include:
• Early detection and the potential of screening studies like PROMISE and iStopMM
• Modifiable risk factors—how diet, exercise, and inflammation shape disease and outcomes
• Emerging therapies on the horizon
• Why “down with dex” and other old beliefs deserve retirement
• The personal “why” behind every advance in myeloma care
About the Experts
Dr. Paul Richardson
Dr. Paul Richardson is an internationally recognized visionary in hematology and oncology whose trailblazing research at Dana-Farber Cancer Institute and Harvard Medical School has driven therapeutic revolutions in multiple myeloma, transforming patient outcomes and defining today’s standards of care. In addition to his involvement in the approval of nearly every major therapy for the disease over the past two decades, he is also one of the most prolific and cited experts in the field, with nearly 500 original articles and 400 reviews.
Dr. Richardson is a paid consultant for BMS.
Dr. Joseph Mikhael
Dr. Joseph Mikhael has revolutionized and broadened access to world-class myeloma care globally through his pioneering leadership at TGen and the International Myeloma Foundation and as principal investigator of numerous groundbreaking clinical trials, setting new benchmarks in innovation, impact, and equity. Celebrated as a dynamic champion for underserved communities, an award-winning educator, and a masterful communicator, Dr. Mikhael has authored over 150 influential scientific articles and was recently recognized among America’s Top 100 Doctors for his transformational contributions to the field.
Dr. Mikhael was not compensated for his participation.
Dr. Mecide Gharibo
Dr. Mecide Gharibo is an innovative hematology leader whose passion for transforming patient care extends from academic clinical expertise at Rutgers Cancer Institute to launching breakthrough therapies as Global Head of Hematology at Bristol Myers Squibb. Renowned for advancing life-saving treatments and optimizing patient access, Dr. Gharibo’s clinical excellence and senior pharmaceutical leadership have fueled medical innovation and set new standards for care through a proven record of successful therapy approvals.
Dr. Gharibo is an employee of BMS.